- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05528679
A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma
September 1, 2022 updated by: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II, Efficacy and Safety Study of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Therapy in Adult Subjects With Severe Eosinophilic Asthma
This study will assess the efficacy and safety of 610 as an adjunctive therapy in adult subjects with severe eosinophilic asthma.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 610 in adults with severe eosinophilic asthma.
Plan to recruit 120 subjects, and the subjects divided into 3 groups: 610 100mg group, 610 300mg group and placebo group.
The study is divided into screening period of 4 weeks, treatment period of 16 weeks and follow-up period of 8 weeks.
Study Type
Interventional
Enrollment (Anticipated)
120
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Qinghong Zhou, MD
- Phone Number: 18911301578
- Email: zhouqinghong@3sbio.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200080
- Shanghai General Hospital
-
Contact:
- Min Zhang, Doctor
- Phone Number: 13482345145
- Email: 13482345145@163.com
-
Contact:
- Xin Zhou, Bachelor
- Phone Number: 13701756821
- Email: xzhou53@163.com
-
Principal Investigator:
- Xin zhou
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Able to understand and follow the protocol requirements, and give written informed consent prior to participation voluntarily in the study
- Female and male aged 18 to 75 years
- Diagnosed with asthma for ≥12 months that meet GINA
- Within 6 months before screening, treatment with medium to high dose inhaled corticosteroid(ICS,inhaled fluticasone at a dosage of at least 500 μg, or equivalent, daily. ICS can be included in In the ICS/LABA combination preparation)and at least one other additional controller medication, such as long-acting β₂ receptor agonist (LABA), leukotriene receptor antagonist (LTRA), theophylline, long-acting Anticholinergic drugs (LAMA), etc. Those medicine must be stable for ≥ 28 days prior to screening and baseline and must continue without dosage changes throughout the study
- Current treatment with maintenance oral corticosteroids (OCS), prednisone dosage must be ≤10 mg, or equivalent, daily, and stable for ≥ 28 days prior to screening and baseline and must continue without dosage changes throughout the study
- In the past 12 months prior to screening, two or more asthma exacerbations history, or at least one time emergency department (ED) visits and/or ICU and/or hospitalization
- Pre-bronchodilator FEV1 <80% predicted value
- Positive of bronchodilator test or positive of bronchial provocation test
- Asthma Control Questionnaire score ≥1.5
- Asthma-related blood eosinophils ≥ 300 cells/μL within 6 months before screening, or asthma-related blood eosinophils ≥ 150 cells/μL at screening
- Male and their partners or female must commit to correct use of one or more effective contraceptive measures of the duration of the trial and for 6 months after the last study drug administration. No fertility, sperm donation, or egg donation plans for at least 6 months after the last study drug administration
Exclusion Criteria:
- With clinically important lung diseases other than asthma that may affect safety or efficacy and evaluated by investigator. This includes lung infection, chronic obstructive pulmonary disease, bronchiectasis, hypersensitivity pneumonitis, pulmonary fibrosis, Allergic bronchopulmonary aspergillosis, etc.
- With other conditions that could lead to elevated eosinophils such as hypereosinophilic syndromes, eosinophilic granulomatosis with polyangiitis (EGPA), or eosinophilic esophagitis
- In past 12 months prior to screening,patients has done bronchial thermoplasty or radiotherapy or plan to do it during of the trial
- with severe cardiac disease or uncontrolled or severe cardiac arrhythmia
- poorly controlled systemic disease
- Active infection that requiring systemic treatment at screening
- Parasitic infection without adequate treatment within 6 months before screening
- Lymphoproliferative disease or any malignancy history within past 5 years prior to screening (Except for received treatment and no recurrence in the past 3 months include basal cell carcinoma, actinic keratosis, carcinoma in situ of cervix, or resected non-invasive malignant colonic polyps.)
- Liver function meets one of the following criteria at screening or before randomization: a) Serum aspartate aminotransferase (AST) or serum alanine aminotransferase (ALT) ≥ 2.0×ULN (upper limit of normal); b) Total bilirubin≥1.5×ULN
- At screening, HBsAg or HCV Ab or HIV Ab or TP Ab positive; HBsAg or HCV Ab positive need to be further tested of HBV DNA titer detection or HCV RNA detection (More than normal value range needs to be excluded)
- Subjects who have received any monoclonal antibody treatment within 3 months or 5 half-lives (whichever is longer) before screening, or with poor treatment effect of anti-IL-5/5R
- Vaccination history with live vaccines (including live attenuated vaccines) within 4 weeks before screening, or plan to receive during of the trial
- Participated in any interventional clinical trial and received intervention within 3 months before screening
- Allergy/intolerance to investigational medicinal product.
- Current smokers with average monthly smoking of ≥10 cigarettes within 6 months before screening, or former smokers with a smoking history of ≥10 pack years (number of pack years = (number of cigarettes per day / 20) x number of years smoked)
- Plan to pregnant during of the trial or pregnant or breastfeeding
- Any other things that are not suitable for participating in this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment group A
610 100 mg administered subcutaneously every 4 weeks
|
100mg administered subcutaneously Q4W
|
Experimental: Treatment group B
610 300 mg administered subcutaneously every 4 weeks
|
300mg administered subcutaneously Q4W
|
Placebo Comparator: placebo Arm Type:no inter
placebo administered subcutaneously every 4 weeks
|
administered subcutaneously Q4W
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in pre-bronchodilator forced expiratory volume in one second (FEV1) at week 16
Time Frame: Baseline (Day 1) and at week 16
|
FEV1 is defined as the volume of air expelled from the lungs in 1 second.
Pre-bronchodilator FEV1 measurements were taken by spirometry.
|
Baseline (Day 1) and at week 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline in pre-bronchodilator forced expiratory volume in one second (FEV1) at weeks 4, 8, and 12
Time Frame: Baseline (Day 1) and at week 4,8,12
|
FEV1 is defined as the volume of air expelled from the lungs in 1 second.
Pre-bronchodilator FEV1 measurements were taken by spirometry.
|
Baseline (Day 1) and at week 4,8,12
|
Percentage change from baseline in pre-bronchodilator forced expiratory volume in one second (FEV1) at weeks 4, 8, 12, 16
Time Frame: Baseline (Day 1) and at week 4,8,12
|
Percentage of FEV1 will be measured using spirometry.
|
Baseline (Day 1) and at week 4,8,12
|
Number of asthma exacerbation through study week 16
Time Frame: From baseline (Day 1) to week 16
|
Asthma exacerbation are defined as worsening of asthma which required use of systemic corticosteroids (≥3 days.
For maintenance of systemic corticosteroids, at least double the existing maintenance dose for at least 3 days was required) and/or hospitalization and/or emergency department (ED) visits.
|
From baseline (Day 1) to week 16
|
Time to first asthma exacerbation event
Time Frame: From baseline (Day 1) to week 16
|
Asthma exacerbation are defined as worsening of asthma which required use of systemic corticosteroids (≥3 days.
For maintenance of systemic corticosteroids, at least double the existing maintenance dose for at least 3 days was required) and/or hospitalization and/or emergency department (ED) visits.
|
From baseline (Day 1) to week 16
|
Number of asthma exacerbations requiring hospitalization (including intubation and ICU admission) or emergency room visits (not conversion to hospitalization)
Time Frame: From baseline (Day 1) to week 16
|
Asthma exacerbations that are associated with a hospitalization or an emergency room visit.
|
From baseline (Day 1) to week 16
|
Number of asthma exacerbations requiring hospitalization (including intubation and ICU admission)
Time Frame: From baseline (Day 1) to week 16
|
Asthma exacerbations that are associated with a hospitalization.
|
From baseline (Day 1) to week 16
|
Puffs of rescue medication for asthma exacerbations
Time Frame: From baseline (Day 1) to week 16
|
Albuterol or levalbuterol for an asthma exacerbation is considered rescue medication.
|
From baseline (Day 1) to week 16
|
Change from baseline in Asthma Control Questionnaire score at week 4,8,12,16
Time Frame: Baseline (Day 1) and at week 4,8,12,16
|
The ACQ has 7 questions- the first 5 items assess the most common asthma symptoms plus 6. short-acting bronchodilator use and 7. FEV1 (pre-bronchodilator use, % and % predicted use).
Patients are asked to recall how their asthma has been during the previous week and to respond to the symptom questions on a 7-point scale (0=no impairment, 6= maximum impairment).
|
Baseline (Day 1) and at week 4,8,12,16
|
Change From Baseline in the St. George's Respiratory Questionnaire Total Score at week 16
Time Frame: Baseline (Day 1) and at week 16
|
The St. George's Respiratory Questionnaire is an established instrument, comprising 50 questions, evaluating symptoms, activity, and impacts; to measure Quality of Life in participants with diseases of airway obstruction and to elicit the participant's opinion of his/her health.
|
Baseline (Day 1) and at week 16
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Qinghong Zhou, MD, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Principal Investigator: Min Zhang, MD, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Principal Investigator: Xin Zhou, MD, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
September 1, 2022
Primary Completion (Anticipated)
September 1, 2023
Study Completion (Anticipated)
September 1, 2023
Study Registration Dates
First Submitted
September 1, 2022
First Submitted That Met QC Criteria
September 1, 2022
First Posted (Actual)
September 6, 2022
Study Record Updates
Last Update Posted (Actual)
September 6, 2022
Last Update Submitted That Met QC Criteria
September 1, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SSGJ-610-BA-II-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on 610 100mg
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...Active, not recruiting
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...Not yet recruiting
-
Sinew Pharma Inc.Not yet recruiting
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineUnknownadd-on Maintenance Treatment of Patients With Severe Eosinophilic AsthmaChina
-
Chong Kun Dang PharmaceuticalCompletedHealthy VolunteersKorea, Republic of
-
MedDay Pharmaceuticals SAUnknownMultiple SclerosisUnited Kingdom, France
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Completed
-
MedDay Pharmaceuticals SAUnknown
-
AstraZenecaCompletedHealthy Japanese VolunteersUnited States